Waters Corporation (NYSE: WAT) Reports Second Quarter 2025 Financial Results
Highlights
-
Sales of
$771 million exceeded guidance range; grew 9% as reported and 8% in constant currency -
GAAP EPS of
$2.47 and non-GAAP EPS of$2.95 , above mid-point of guidance range - Instruments grew mid-single-digits in constant currency, led by high-single-digit LC and MS growth – with continued strength in instrument replacement, particularly among large pharma and CDMO customers
- Recurring revenue grew 11% in constant currency, with 9% service growth and double-digit chemistry growth
- In constant currency, Pharma grew 11% and Industrial grew 6%, while Academic & Government declined 3%, performing better than expected
-
Raising full-year 2025 constant currency sales growth guidance to +5.5% to +7.5% and raising full-year 2025 non-GAAP EPS guidance to
$12.95 to$13.05
Second Quarter 2025
Sales for the second quarter of 2025 were
On a GAAP basis, diluted earnings per share (EPS) for the second quarter of 2025 was
"Our team continues to execute extremely well and we delivered excellent results again this quarter, driven by robust instrument replacement trends–particularly among large pharma and CDMO customers," said Dr.
A description and reconciliation of GAAP to non-GAAP results appear in the tables below and can be found on the Company's website www.waters.com in the Investor Relations section.
Full-Year and Third Quarter 2025 Financial Guidance
Full-Year 2025 Financial Guidance
The Company is raising its full-year 2025 constant currency sales growth guidance to the range of +5.5% to +7.5%. Net of currency translation, the Company is raising its full-year 2025 reported sales growth to the range of +5.0% to +7.0%.
The Company is raising its full-year 2025 non-GAAP EPS guidance to the range of
Third Quarter 2025 Financial Guidance
The Company expects third quarter 2025 constant currency sales growth in the range of +5.0% to +7.0%. Net of currency translation, third quarter 2025 reported sales growth is expected in the range of +4.5% to +6.5%.
The Company expects third quarter 2025 non-GAAP EPS to be in the range of
Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the full-year and third quarter.
Conference Call Details
About
Additional Information and Where to Find It
This release is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or exchange any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. It does not constitute a prospectus or prospectus equivalent document. No offering or sale of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the "Securities Act"), and otherwise in accordance with applicable law.
In connection with the proposed transaction between Waters,
Participants in the Solicitation
Waters and BD and their respective directors and executive officers may be considered participants in the solicitation of proxies from Waters' stockholders in connection with the proposed transaction. Information about the directors and executive officers of Waters is set forth in its Annual Report on Form 10-K for the year ended
Non-GAAP Financial Measures
This release contains financial measures, such as constant currency growth rates, adjusted operating income, adjusted net income, adjusted earnings per diluted share and free cash flow, among others, which are considered "non-GAAP" financial measures under applicable
Cautionary Statement
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "feels", "believes", "anticipates", "plans", "expects", "intends", "suggests", "appears", "estimates", "projects" and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. Our actual future results may differ significantly from the results discussed in the forward-looking statements within this release for a variety of reasons, including and without limitation, risks or uncertainties related to expectations regarding our strategy, our future financial and operational performance, future economic and market conditions, including our expectations about the growth rates of certain markets, our strategic initiatives, including our instrument replacement initiatives, respond and adapt to changing global dynamics, including the potential impacts of tariffs and supply chain challenges, our ability to retain and attract customers in various geographies and market segments, our market size and growth opportunities, our competitive positioning, projected costs, technological capabilities and plans, and objectives of management. Furthermore, important factors related to the proposed transaction between Waters, BD and
|
|||||||
Consolidated Statements of Operations |
|||||||
(In thousands, except per share data) |
|||||||
(Unaudited) |
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
Three Months Ended |
|
Six Months Ended |
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales |
$ 771,332 |
|
$ 708,529 |
|
$ 1,433,037 |
|
$ 1,345,368 |
|
|
|
|
|
|
|
|
Costs and operating expenses: |
|
|
|
|
|
|
|
Cost of sales |
321,407 |
|
288,244 |
|
598,152 |
|
550,030 |
Selling and administrative expenses |
201,257 |
|
173,247 |
|
376,138 |
|
347,783 |
Research and development expenses |
48,548 |
|
46,182 |
|
95,170 |
|
90,777 |
Purchased intangibles amortization |
11,907 |
|
11,744 |
|
23,619 |
|
23,578 |
Litigation provision |
- |
|
- |
|
- |
|
10,242 |
|
|
|
|
|
|
|
|
Operating income |
188,213 |
|
189,112 |
|
339,958 |
|
322,958 |
|
|
|
|
|
|
|
|
Other (expense) income, net |
(676) |
|
(302) |
|
848 |
|
1,957 |
Interest expense, net |
(9,847) |
|
(19,398) |
|
(20,228) |
|
(40,647) |
|
|
|
|
|
|
|
|
Income from operations before income taxes |
177,690 |
|
169,412 |
|
320,578 |
|
284,268 |
|
|
|
|
|
|
|
|
Provision for income taxes |
30,579 |
|
26,675 |
|
52,086 |
|
39,335 |
|
|
|
|
|
|
|
|
Net income |
$ 147,111 |
|
$ 142,737 |
|
$ 268,492 |
|
$ 244,933 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per basic common share |
$ 2.47 |
|
$ 2.41 |
|
$ 4.51 |
|
$ 4.13 |
|
|
|
|
|
|
|
|
Weighted-average number of basic common shares |
59,515 |
|
59,339 |
|
59,478 |
|
59,287 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per diluted common share |
$ 2.47 |
|
$ 2.40 |
|
$ 4.50 |
|
$ 4.12 |
|
|
|
|
|
|
|
|
Weighted-average number of diluted common shares and equivalents |
59,656 |
|
59,451 |
|
59,686 |
|
59,445 |
|
|
|
|
|
|
|
|
|
|||||||||||||||
Reconciliation of GAAP to Adjusted Non-GAAP |
|||||||||||||||
|
|||||||||||||||
Three Months Ended |
|||||||||||||||
(In thousands) |
|||||||||||||||
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Constant |
|
|
|
|
|
Three Months Ended |
|
Percent |
|
Impact of |
|
Currency |
||||
|
|
|
|
|
|
|
|
|
Change |
|
Currency |
|
Growth Rate (a) |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Waters |
|
|
$ |
688,837 |
|
$ |
622,561 |
|
11 % |
|
1 % |
|
10 % |
||
TA |
|
|
|
|
82,495 |
|
|
85,968 |
|
(4 %) |
|
2 % |
|
(6 %) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
$ |
771,332 |
|
$ |
708,529 |
|
9 % |
|
1 % |
|
8 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Instruments |
|
|
$ |
308,415 |
|
$ |
294,059 |
|
5 % |
|
1 % |
|
4 % |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Service |
|
|
|
297,932 |
|
|
273,385 |
|
9 % |
|
0 % |
|
9 % |
||
Chemistry |
|
|
|
164,985 |
|
|
141,085 |
|
17 % |
|
1 % |
|
16 % |
||
Total Recurring |
|
|
|
462,917 |
|
|
414,470 |
|
12 % |
|
1 % |
|
11 % |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
$ |
771,332 |
|
$ |
708,529 |
|
9 % |
|
1 % |
|
8 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
265,940 |
|
$ |
237,431 |
|
12 % |
|
(2 %) |
|
14 % |
|
|
|
|
|
280,740 |
|
|
274,468 |
|
2 % |
|
0 % |
|
2 % |
||
|
|
|
|
224,652 |
|
|
196,630 |
|
14 % |
|
6 % |
|
8 % |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
$ |
771,332 |
|
$ |
708,529 |
|
9 % |
|
1 % |
|
8 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
$ |
461,968 |
|
$ |
415,747 |
|
11 % |
|
1 % |
|
11 % |
||
Industrial |
|
|
|
237,655 |
|
|
221,385 |
|
7 % |
|
1 % |
|
6 % |
||
Academic & Government |
|
|
71,709 |
|
|
71,397 |
|
0 % |
|
3 % |
|
(3 %) |
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
$ |
771,332 |
|
$ |
708,529 |
|
9 % |
|
1 % |
|
8 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a) |
|
The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Reconciliation of GAAP to Adjusted Non-GAAP |
||||||||||||||||
|
||||||||||||||||
Six Months Ended |
||||||||||||||||
(In thousands) |
||||||||||||||||
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Constant |
|
|
|
|
|
|
Six Months Ended |
|
Percent |
|
Impact of |
|
Currency |
|
||||
|
|
|
|
|
|
|
|
|
Change |
|
Currency |
|
Growth Rate (a) |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Waters |
|
|
$ |
1,276,134 |
|
$ |
1,184,460 |
|
8 % |
|
(1 %) |
|
9 % |
|
||
TA |
|
|
|
|
156,903 |
|
|
160,908 |
|
(2 %) |
|
1 % |
|
(3 %) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
$ |
1,433,037 |
|
$ |
1,345,368 |
|
7 % |
|
(1 %) |
|
7 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Instruments |
|
|
$ |
571,308 |
|
$ |
536,003 |
|
7 % |
|
(1 %) |
|
7 % |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Service |
|
|
|
559,107 |
|
|
534,073 |
|
5 % |
|
(1 %) |
|
6 % |
|
||
Chemistry |
|
|
|
302,622 |
|
|
275,292 |
|
10 % |
|
0 % |
|
10 % |
|
||
Total Recurring |
|
|
|
861,729 |
|
|
809,365 |
|
6 % |
|
(1 %) |
|
8 % |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
$ |
1,433,037 |
|
$ |
1,345,368 |
|
7 % |
|
(1 %) |
|
7 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
486,716 |
|
$ |
444,990 |
|
9 % |
|
(4 %) |
|
13 % |
|
|
|
|
|
|
536,277 |
|
|
515,639 |
|
4 % |
|
0 % |
|
4 % |
|
||
|
|
|
|
410,044 |
|
|
384,739 |
|
7 % |
|
2 % |
|
5 % |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
$ |
1,433,037 |
|
$ |
1,345,368 |
|
7 % |
|
(1 %) |
|
7 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
$ |
853,019 |
|
$ |
789,954 |
|
8 % |
|
(1 %) |
|
9 % |
|
||
Industrial |
|
|
|
441,020 |
|
|
416,719 |
|
6 % |
|
0 % |
|
6 % |
|
||
Academic & Government |
|
|
138,998 |
|
|
138,695 |
|
0 % |
|
0 % |
|
0 % |
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
$ |
1,433,037 |
|
$ |
1,345,368 |
|
7 % |
|
(1 %) |
|
7 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a) |
|
The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||
Reconciliation of GAAP to Adjusted Non-GAAP Financials |
|||||||||||||||||||||||||||||
Three and Six Months Ended |
|||||||||||||||||||||||||||||
(In thousands, except per share data) |
|||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling & |
|
|
Research & |
|
|
|
|
|
Operating |
|
|
Other |
|
|
before |
|
|
Provision for |
|
|
|
|
|
Diluted |
|
|
|
|
|
Administrative |
|
|
Development |
|
|
Operating |
|
|
Income |
|
|
(Expense) |
|
|
Income |
|
|
Income |
|
|
Net |
|
|
Earnings |
|
|
|
|
|
Expenses (a) |
|
|
Expenses |
|
|
Income |
|
|
Percentage |
|
|
Income |
|
|
Taxes |
|
|
Taxes |
|
|
Income |
|
|
per Share |
Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
GAAP |
|
|
$ |
213,164 |
|
$ |
48,548 |
|
$ |
188,213 |
|
|
24.4 % |
|
$ |
(676) |
|
$ |
177,690 |
|
$ |
30,579 |
|
$ |
147,111 |
|
$ |
2.47 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchased intangibles amortization (b) |
|
|
(11,907) |
|
|
- |
|
|
11,907 |
|
|
1.5 % |
|
|
- |
|
|
11,907 |
|
|
2,820 |
|
|
9,087 |
|
|
0.15 |
|
|
Restructuring costs and certain other items (c) |
|
|
(3,869) |
|
|
- |
|
|
3,869 |
|
|
0.5 % |
|
|
- |
|
|
3,869 |
|
|
912 |
|
|
2,957 |
|
|
0.05 |
|
|
ERP implementation and transformation costs (d) |
|
|
(5,082) |
|
|
- |
|
|
5,082 |
|
|
0.7 % |
|
|
- |
|
|
5,082 |
|
|
1,220 |
|
|
3,862 |
|
|
0.06 |
|
|
Acquisition related costs (e) |
|
|
(14,284) |
|
|
- |
|
|
14,284 |
|
|
1.9 % |
|
|
- |
|
|
14,284 |
|
|
2,391 |
|
|
11,893 |
|
|
0.20 |
|
|
Retention bonus obligation (g) |
|
|
(955) |
|
|
(318) |
|
|
1,273 |
|
|
0.2 % |
|
|
- |
|
|
1,273 |
|
|
305 |
|
|
968 |
|
|
0.02 |
|
Adjusted Non-GAAP |
|
$ |
177,067 |
|
$ |
48,230 |
|
$ |
224,628 |
|
|
29.1 % |
|
$ |
(676) |
|
$ |
214,105 |
|
$ |
38,227 |
|
$ |
175,878 |
|
$ |
2.95 |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
GAAP |
|
|
$ |
184,991 |
|
$ |
46,182 |
|
$ |
189,112 |
|
|
26.7 % |
|
$ |
(302) |
|
$ |
169,412 |
|
$ |
26,675 |
|
$ |
142,737 |
|
$ |
2.40 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchased intangibles amortization (b) |
|
|
(11,744) |
|
|
- |
|
|
11,744 |
|
|
1.7 % |
|
|
- |
|
|
11,744 |
|
|
2,810 |
|
|
8,934 |
|
|
0.15 |
|
|
Restructuring costs and certain other items (c) |
|
|
(1,139) |
|
|
- |
|
|
1,139 |
|
|
0.2 % |
|
|
- |
|
|
1,139 |
|
|
280 |
|
|
859 |
|
|
0.01 |
|
|
Retention bonus obligation (g) |
|
|
(3,817) |
|
|
(1,272) |
|
|
5,089 |
|
|
0.7 % |
|
|
- |
|
|
5,089 |
|
|
1,221 |
|
|
3,868 |
|
|
0.07 |
|
Adjusted Non-GAAP |
|
$ |
168,291 |
|
$ |
44,910 |
|
$ |
207,084 |
|
|
29.2 % |
|
$ |
(302) |
|
$ |
187,384 |
|
$ |
30,986 |
|
$ |
156,398 |
|
$ |
2.63 |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
GAAP |
|
|
$ |
399,757 |
|
$ |
95,170 |
|
$ |
339,958 |
|
|
23.7 % |
|
$ |
848 |
|
$ |
320,578 |
|
$ |
52,086 |
|
$ |
268,492 |
|
$ |
4.50 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchased intangibles amortization (b) |
|
|
(23,619) |
|
|
- |
|
|
23,619 |
|
|
1.6 % |
|
|
- |
|
|
23,619 |
|
|
5,652 |
|
|
17,967 |
|
|
0.30 |
|
|
Restructuring costs and certain other items (c) |
|
|
(4,467) |
|
|
- |
|
|
4,467 |
|
|
0.3 % |
|
|
- |
|
|
4,467 |
|
|
1,056 |
|
|
3,411 |
|
|
0.06 |
|
|
ERP implementation and transformation costs (d) |
|
|
(7,377) |
|
|
- |
|
|
7,377 |
|
|
0.5 % |
|
|
- |
|
|
7,377 |
|
|
1,771 |
|
|
5,606 |
|
|
0.09 |
|
|
Acquisition related costs (e) |
|
|
(14,284) |
|
|
- |
|
|
14,284 |
|
|
1.0 % |
|
|
- |
|
|
14,284 |
|
|
2,391 |
|
|
11,893 |
|
|
0.20 |
|
|
Retention bonus obligation (g) |
|
|
(2,864) |
|
|
(954) |
|
|
3,818 |
|
|
0.3 % |
|
|
- |
|
|
3,818 |
|
|
916 |
|
|
2,902 |
|
|
0.05 |
|
Adjusted Non-GAAP |
|
$ |
347,146 |
|
$ |
94,216 |
|
$ |
393,523 |
|
|
27.5 % |
|
$ |
848 |
|
$ |
374,143 |
|
$ |
63,872 |
|
$ |
310,271 |
|
$ |
5.20 |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
GAAP |
|
|
$ |
381,603 |
|
$ |
90,777 |
|
$ |
322,958 |
|
|
24.0 % |
|
$ |
1,957 |
|
$ |
284,268 |
|
$ |
39,335 |
|
$ |
244,933 |
|
$ |
4.12 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchased intangibles amortization (b) |
|
|
(23,578) |
|
|
- |
|
|
23,578 |
|
|
1.8 % |
|
|
- |
|
|
23,578 |
|
|
5,642 |
|
|
17,936 |
|
|
0.30 |
|
|
Restructuring costs and certain other items (c) |
|
|
(9,486) |
|
|
- |
|
|
9,486 |
|
|
0.7 % |
|
|
- |
|
|
9,486 |
|
|
2,335 |
|
|
7,151 |
|
|
0.12 |
|
|
Litigation provision and settlement (f) |
|
|
(10,242) |
|
|
- |
|
|
10,242 |
|
|
0.8 % |
|
|
- |
|
|
10,242 |
|
|
2,458 |
|
|
7,784 |
|
|
0.13 |
|
|
Retention bonus obligation (g) |
|
|
(9,542) |
|
|
(3,181) |
|
|
12,723 |
|
|
0.9 % |
|
|
- |
|
|
12,723 |
|
|
3,053 |
|
|
9,670 |
|
|
0.16 |
|
Adjusted Non-GAAP |
|
$ |
328,755 |
|
$ |
87,596 |
|
$ |
378,987 |
|
|
28.2 % |
|
$ |
1,957 |
|
$ |
340,297 |
|
$ |
52,823 |
|
$ |
287,474 |
|
$ |
4.84 |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
(a) |
Selling & administrative expenses include purchased intangibles amortization and litigation provisions and settlements. |
||||||||||||||||||||||||||||
(b) |
The purchased intangibles amortization, a non-cash expense, was excluded to be consistent with how management evaluates the performance of its core business against historical operating results and the operating results of competitors over periods of time. |
||||||||||||||||||||||||||||
(c) |
Restructuring costs and certain other items were excluded as the Company believes that the cost to consolidate operations, reduce overhead, and certain other income or expense items are not normal and do not represent future ongoing business expenses of a specific function or geographic location of the Company. |
||||||||||||||||||||||||||||
(d) |
ERP implementation and transformation costs represent costs related to the Company's initiative to transition from its legacy enterprise resource planning (ERP) system to a new global ERP solution with a cloud-based infrastructure. These costs, which do not represent normal or future ongoing business expenses, are one-time, non-recurring costs related to the establishment of our new global ERP solution that were determined to be non-capitalizable in accordance with accounting standards. |
||||||||||||||||||||||||||||
(e) |
Acquisition related costs include all incremental costs incurred to effect the business combination, such as advisory, legal, accounting, tax, valuation, and other professional fees. The Company believes that these costs are not normal and do not represent future ongoing business expenses. |
||||||||||||||||||||||||||||
(f) |
Litigation provisions and settlement gains were excluded as these items are isolated, unpredictable and not expected to recur regularly. |
||||||||||||||||||||||||||||
(g) |
In connection with the Wyatt acquisition, the Company recognized a two-year retention bonus obligation that is contingent upon the employee's providing future service and continued employment with Waters. The Company believes that these costs are not normal and do not represent future ongoing business expenses. |
|
|||||||
Preliminary Condensed Unclassified Consolidated Balance Sheets |
|||||||
(In thousands and unaudited) |
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
$ 367,215 |
|
$ 325,355 |
||
Accounts receivable |
|
|
|
730,074 |
|
733,365 |
|
Inventories |
|
|
|
540,754 |
|
477,261 |
|
Property, plant and equipment, net |
|
645,267 |
|
651,200 |
|||
Intangible assets, net |
|
|
|
579,127 |
|
567,906 |
|
|
|
|
|
|
1,337,908 |
|
1,295,720 |
Other assets |
|
|
|
517,730 |
|
502,988 |
|
Total assets |
|
|
|
$ 4,718,075 |
|
$ 4,553,795 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable and debt |
|
|
$ 1,456,966 |
|
$ 1,626,488 |
||
Other liabilities |
|
|
|
1,101,297 |
|
1,098,800 |
|
Total liabilities |
|
|
|
2,558,263 |
|
2,725,288 |
|
|
|
|
|
|
|
|
|
Total stockholders' equity |
|
|
2,159,812 |
|
1,828,507 |
||
Total liabilities and stockholders' equity |
|
$ 4,718,075 |
|
$ 4,553,795 |
|
|||||||||||
Preliminary Condensed Consolidated Statements of Cash Flows |
|||||||||||
Three and Six Months Ended |
|||||||||||
(In thousands and unaudited) |
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Six Months Ended |
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
|||
|
Net income |
$ 147,111 |
|
$ 142,737 |
|
|
$ 268,492 |
|
$ 244,933 |
||
|
Adjustments to reconcile net income to net |
|
|
|
|
|
|
|
|
||
|
|
|
cash provided by operating activities: |
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
13,097 |
|
11,433 |
|
|
25,975 |
|
22,346 |
|
|
|
Depreciation and amortization |
51,649 |
|
47,229 |
|
|
101,018 |
|
95,743 |
|
|
|
Change in operating assets and liabilities and other, net |
(170,716) |
|
(146,865) |
|
|
(94,791) |
|
(45,618) |
|
|
|
|
Net cash provided by operating activities |
41,141 |
|
54,534 |
|
|
300,694 |
|
317,404 |
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|||
|
Additions to property, plant, equipment |
|
|
|
|
|
|
|
|
||
|
|
|
and software capitalization |
(22,594) |
|
(36,104) |
|
|
(48,336) |
|
(64,759) |
|
Business acquisitions, net of cash acquired |
(34,969) |
|
- |
|
|
(34,969) |
|
- |
||
|
Investments in unaffiliated companies |
(789) |
|
- |
|
|
(1,295) |
|
(1,064) |
||
|
Net change in investments |
- |
|
(11) |
|
|
- |
|
(36) |
||
|
|
|
Net cash used in investing activities |
(58,352) |
|
(36,115) |
|
|
(84,600) |
|
(65,859) |
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|||
|
Net change in debt |
(4,506) |
|
(50,000) |
|
|
(174,506) |
|
(350,000) |
||
|
Proceeds from stock plans |
4,492 |
|
7,904 |
|
|
12,738 |
|
21,836 |
||
|
Purchases of treasury shares |
(375) |
|
(245) |
|
|
(14,309) |
|
(13,334) |
||
|
Other cash flow from financing activities, net |
(639) |
|
8,304 |
|
|
1,802 |
|
15,285 |
||
|
|
|
Net cash used in financing activities |
(1,028) |
|
(34,037) |
|
|
(174,275) |
|
(326,213) |
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents |
2,582 |
|
4,755 |
|
|
41 |
|
6,019 |
|||
|
|
|
(Decrease) increase in cash and cash equivalents |
(15,657) |
|
(10,863) |
|
|
41,860 |
|
(68,649) |
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at beginning of period |
382,872 |
|
337,290 |
|
|
325,355 |
|
395,076 |
|||
|
|
|
Cash and cash equivalents at end of period |
$ 367,215 |
|
$ 326,427 |
|
|
$ 367,215 |
|
$ 326,427 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of GAAP Cash Flows from Operating Activities to Free Cash Flow (a) |
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities - GAAP |
$ 41,141 |
|
$ 54,534 |
|
|
$ 300,694 |
|
$ 317,404 |
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments: |
|
|
|
|
|
|
|
|
||
|
|
Additions to property, plant, equipment |
|
|
|
|
|
|
|
|
|
|
|
|
and software capitalization |
(22,594) |
|
(36,104) |
|
|
(48,336) |
|
(64,759) |
|
|
Tax reform payments |
120,006 |
|
95,645 |
|
|
120,006 |
|
95,645 |
|
|
|
Litigation settlements paid, net |
- |
|
9,625 |
|
|
- |
|
9,250 |
|
|
|
Payment of Wyatt retention bonus obligation (b) |
20,127 |
|
19,770 |
|
|
20,127 |
|
19,770 |
|
Free Cash Flow - Adjusted Non-GAAP |
$ 158,680 |
|
$ 143,470 |
|
|
$ 392,491 |
|
$ 377,310 |
|||
|
|
|
|
|
|
|
|
|
|
|
|
(a) |
The Company defines free cash flow as net cash flow from operations accounted for under GAAP less capital expenditures and software capitalizations plus or minus any unusual and non recurring items. Free cash flow is not a GAAP measurement and may not be comparable to free cash flow reported by other companies. |
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
(b) |
During the six months ended |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Reconciliation of Projected GAAP to Adjusted Non-GAAP Financial Outlook |
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Twelve Months Ended |
|
Three Months Ended |
|
||||
|
|
|
|
|
|
|
||||
|
|
|
|
Range |
|
|
|
Range |
|
|
Projected Sales |
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
Constant currency sales growth rate (a) |
5.5 % |
- |
7.5 % |
|
5.0 % |
- |
7.0 % |
|
||
Currency translation impact |
(0.5 %) |
- |
(0.5 %) |
|
(0.5 %) |
- |
(0.5 %) |
|
||
Sales growth rate as reported |
5.0 % |
- |
7.0 % |
|
4.5 % |
- |
6.5 % |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Range |
|
|
|
Range |
|
|
Projected Earnings Per Diluted Share |
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
GAAP earnings per diluted share |
$ 11.45 |
- |
$ 11.55 |
|
$ 2.70 |
- |
$ 2.80 |
|
||
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
Purchased intangibles amortization |
$ 0.60 |
- |
$ 0.60 |
|
$ 0.15 |
- |
$ 0.15 |
|
|
|
Restructuring costs and certain other items |
$ 0.07 |
- |
$ 0.07 |
|
$ 0.01 |
- |
$ 0.01 |
|
|
|
ERP implementation and transformation costs |
$ 0.25 |
- |
$ 0.25 |
|
$ 0.08 |
- |
$ 0.08 |
|
|
|
Acquisition related costs |
$ 0.53 |
- |
$ 0.53 |
|
$ 0.21 |
- |
$ 0.21 |
|
|
|
Retention bonus obligation |
$ 0.05 |
- |
$ 0.05 |
|
$ - |
- |
$ - |
|
|
Adjusted non-GAAP earnings per diluted share |
$ 12.95 |
- |
$ 13.05 |
|
$ 3.15 |
- |
$ 3.25 |
|
||
|
|
|
|
|
|
|
|
|
|
|
(a) Constant currency growth rates are a non-GAAP financial measure that measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period. These amounts are estimated at the current foreign currency exchange rates and based on the forecasted geographical sales in local currency, as well as an assessment of market conditions as of today, and may differ significantly from actual results. |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
These forward-looking adjustment estimates do not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance. |
|
|||||||||
|
||||||||||
|
Contact:
View original content:https://www.prnewswire.com/news-releases/waters-corporation-nyse-wat-reports-second-quarter-2025-financial-results-302520299.html
SOURCE